Newspaper Advertisement- Audited Consolidated and Standalone Financial Results for the quarter and financial year ended March 31, 2026
TATACHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Tata Chemicals reported Q4 FY26 consolidated revenue of ₹3,438 crore, marginally lower than Q4 FY25's ₹3,509 crore. However, the company posted a consolidated loss of ₹2,116 crore for Q4 due to exceptional items worth ₹2,015 crore (primarily write-downs related to Tuticorin operations and investments). For the full year FY26, consolidated revenue was ₹14,584 crore vs ₹14,887 crore in FY25 — a slight decline of ~2%. The consolidated loss for FY26 stood at ₹1,715 crore against a profit of ₹354 crore in FY25, largely driven by exceptional items of ₹1,626 crore. On a standalone basis, FY26 revenue grew 8.8% to ₹4,831 crore from ₹4,441 crore, with PAT rising 15.6% to ₹606 crore from ₹524 crore, showing healthy underlying business performance despite a weaker Q4 PAT of ₹48 crore vs ₹97 crore in Q4 FY25. Net worth stands at ₹22,175 crore (consolidated) and ₹19,308 crore (standalone). Total standalone debt is ₹3,487 crore.
The exceptional items obliterated consolidated profitability, masking a reasonably strong standalone performance. Investors should focus on the standalone results showing revenue and profit growth, while the consolidated loss is largely a non-cash accounting impact. The stock may remain under pressure due to the large consolidated loss but the standalone business trajectory is positive.